Table 1. Patient characteristics and LY2603618 sensitivity in primary AML patient samples (n = 26).

Patient	Gender	Age (year)	Disease status	FAB subtype	Cytogenetics	Blast purity (%)	LY2603618 IC50 (μM)	Relative CHK1 transcripts
AML#8	Male	55	Newly diagnosed	M2	46, XY	31.5	5.6	0.04
AML#9	Female	35	Relapsed	M5	47, XX,+10,t(16;21)(p11;q22),add(11p)	87	2.6	0.04
AML#10	Male	23	Newly diagnosed	M2	46, XY, del(9q)	52.5	1.2	0.20
AML#11	Female	43	Newly diagnosed	M2	46, XX	91	1.8	0.03
AML#12	Male	6	Newly diagnosed	M3	46, XY, t (15;17) (q22;q21)	85	3.8	0.14
AML#15	Female	63	Newly diagnosed	M2	46, XX	23	1.6	0.04
AML#16	Male	38	Newly diagnosed	M3	46, XY, t (15;17) (q22;q21)	90	1.3	0.02
AML#17	Female	45	Newly diagnosed	M4	46, XX	35.5	18.2	0.21
AML#18	Female	19	Relapsed	M2	46, XX, t (8;21) (q22;q22)/46, XX	54	2.3	0.20
AML#19	Male	4	Newly diagnosed	M4	46, XY	40.5	8.3	0.40
AML#21	Male	42	Newly diagnosed	M4	46, XY/44, XY, −17, −19, (11q-?)	51	3.2	0.44
AML#23	Male	60	Newly diagnosed	M5	48, XY,+2,+8, i (12) (q10)/46, XY	81	3.9	1.65
AML#24	Male	59	Newly diagnosed	M2	46, XY	42	19.3	0.03
AML#25	Female	12	Newly diagnosed	M3	46, XX, t (15;17) (q22;q21)/46, XX	88	1.1	0.16
AML#27	female	41	Relapsed	M4	47, XX, del (5q), +8, t (15;18) (q12,q23)	24	19.6	0.15
AML#29	Male	9	Newly diagnosed	M4	46, XY, t (6; 9) (p22;q34)/46, XY	31	1.5	0.08
AML#31	Male	17	Newly diagnosed	M2	46, XY	68.5	0.7	1.17
AML#33	Female	76	Newly diagnosed	M5	46, XX	84.5	3.5	1.55
AML#35	Male	65	Newly diagnosed	M5	47, XY, add (7q), −16, −17, +marx3	76	17.8	0.89
AML#36	Male	43	Newly diagnosed	M2	46, XY, t (8;21) (q22;q22)	48	2.7	0.50
AML#39	Male	50	Newly diagnosed	M2	45, X, -Y, t (8;21) (q22;q22), del (11q)	46	4.0	0.24
AML#40	Male	12	Newly diagnosed	M3	46, XY, t (15;17) (q22;q21)	92.5	2.6	0.19
AML#41	Male	74	Newly diagnosed	M5	47, XY,+8	95	6.5	0.23
AML#43	Male	19	Newly diagnosed	M2	45, X, -Y, t (8;21) (q22;q22), del (9q)	47	3.4	0.85
AML#44	Male	25	Newly diagnosed	M3	46, XY, t (15;17) (q22;q21)	94	3.2	0.50
AML#45	Male	48	Relapsed	M2	46, XY, t (7;11) (p15;p15)	39.5	3.6	1.04